Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Shares Bought by Nebula Research & Development LLC

Nebula Research & Development LLC boosted its position in shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPHFree Report) by 93.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 64,159 shares of the company’s stock after buying an additional 30,990 shares during the period. Nebula Research & Development LLC owned 0.08% of Deciphera Pharmaceuticals worth $1,035,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in DCPH. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Deciphera Pharmaceuticals by 2.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 41,527 shares of the company’s stock valued at $670,000 after purchasing an additional 1,117 shares during the period. Principal Financial Group Inc. increased its holdings in shares of Deciphera Pharmaceuticals by 10.3% in the third quarter. Principal Financial Group Inc. now owns 18,266 shares of the company’s stock valued at $232,000 after purchasing an additional 1,699 shares during the period. Quest Partners LLC acquired a new position in shares of Deciphera Pharmaceuticals in the fourth quarter valued at approximately $30,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Deciphera Pharmaceuticals by 20.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,178 shares of the company’s stock worth $196,000 after purchasing an additional 2,102 shares in the last quarter. Finally, Exchange Traded Concepts LLC boosted its position in Deciphera Pharmaceuticals by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 10,447 shares of the company’s stock worth $169,000 after purchasing an additional 2,649 shares in the last quarter. Institutional investors and hedge funds own 70.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on DCPH shares. Jefferies Financial Group reiterated a “hold” rating and set a $25.60 target price (down from $26.00) on shares of Deciphera Pharmaceuticals in a research report on Monday, April 29th. JPMorgan Chase & Co. boosted their target price on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a “neutral” rating in a research report on Wednesday, March 20th. Jonestrading reiterated a “hold” rating and set a $25.60 target price on shares of Deciphera Pharmaceuticals in a research report on Monday, April 29th. JMP Securities reiterated a “market perform” rating on shares of Deciphera Pharmaceuticals in a research report on Tuesday, April 30th. Finally, Guggenheim reiterated a “neutral” rating on shares of Deciphera Pharmaceuticals in a research report on Tuesday, April 30th. Seven research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Deciphera Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $24.17.

Check Out Our Latest Analysis on Deciphera Pharmaceuticals

Deciphera Pharmaceuticals Stock Performance

NASDAQ DCPH traded up $0.02 during trading hours on Tuesday, hitting $25.59. 1,596,089 shares of the company’s stock were exchanged, compared to its average volume of 1,288,416. The business’s 50 day moving average is $21.46 and its 200-day moving average is $17.42. Deciphera Pharmaceuticals, Inc. has a 12-month low of $9.90 and a 12-month high of $25.61.

Deciphera Pharmaceuticals (NASDAQ:DCPHGet Free Report) last released its quarterly earnings data on Friday, May 10th. The company reported ($0.52) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.03. The company had revenue of $45.00 million for the quarter, compared to the consensus estimate of $45.99 million. Deciphera Pharmaceuticals had a negative return on equity of 52.42% and a negative net margin of 108.86%. On average, research analysts predict that Deciphera Pharmaceuticals, Inc. will post -2.15 earnings per share for the current year.

About Deciphera Pharmaceuticals

(Free Report)

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.

Further Reading

Institutional Ownership by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.